Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 470

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 470
---
 2024, consists of (i) 2,849,402 shares                                                                                                                                           
 of common stock that are held by Avoro Capital Advisors LLC (“Avoro Capital”) and (ii) 622,350 shares of common stock that are held by Avoro Ventures Fund L.P. (“Avoro Ventures Fund”), an investment fund managed by Avoro Ventures                
 LLC (“Avoro Ventures”). The beneficial ownership shown above excludes (i) 6,666,400 shares issuable pursuant to Pre-Funded Warrants to be purchased in the PIPE Offering by Avoro Life Sciences Fund                                                 
 LLC and (ii) 1,666,600 shares issuable pursuant to Pre-Funded Warrants to be purchased in the PIPE Offering by Avoro Ventures Fund. According to the Schedule 13D/A, Avoro Capital has sole voting power and sole                                    
 dispositive power with regard to 2,849,402 shares of common stock and Avoro Ventures has sole dispositive power with regard to 622,350 shares of common stock. Behzad Aghazadeh, a director of the Company, is the portfolio manager and controlling 
 person at Avoro Capital and Avoro Ventures. The principal business address of each of Avoro Capital and Mr. Aghazadeh is 110 Greene Street, Suite 800, New York, NY 10012.                                                                           |

| (2) | Consists of (i) 1,217,580 shares to be purchased in the PIPE Offering by Acuta Capital Fund, L.P. (“Acuta                                                                                                 
 Capital”); (ii) 343,420 shares to be purchased in the PIPE Offering by Acuta Opportunity Fund, L.P. (“Acuta Opportunity Fund”); (iii) 1,572,698 shares previously held by Acuta Capital; and (iv) 276,704 |

- 318 -

| shares previously held by Acuta Opportunity Fund. Acuta Capital Partners, LLC (“Acuta Partners”) is a general partner of each of Acuta Capital and Acuta Opportunity Fund. According to                                                                 
 the Schedule 13F, Acuta Partners has sole voting power and sole dispositive power with regard to 1,849,402 shares of common stock. Dr. Dalal, a director of the Company, is the Chief Investment Officer and Managing Member of Acuta Partners.         
 Dr. Dalal has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund.